Declared Dividend • May 31
Final dividend of kr1.20 announced Shareholders will receive a dividend of kr1.20. Ex-date: 4th September 2026 Payment date: 10th September 2026 Dividend yield will be 27%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is being paid despite the company being loss-making over the last 12 months. However, the dividend is covered by cash flows (66% cash payout ratio). The dividend has increased by an average of 17% per year over the past 10 years. However, payments have been volatile during that time. Reported Earnings • May 28
Full year 2026 earnings released: kr1.36 loss per share (vs kr0.62 profit in FY 2025) Full year 2026 results: kr1.36 loss per share (down from kr0.62 profit in FY 2025). Revenue: kr16.7b (down 7.2% from FY 2025). Net loss: kr519.0m (down 319% from profit in FY 2025). Revenue is forecast to grow 5.5% p.a. on average during the next 3 years, compared to a 5.9% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 55 percentage points per year, which is a significant difference in performance. Board Change • May 21
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Independent Director Jan De Witte was the last director to join the board, commencing their role in 2025. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Annuncio • May 19
Elekta AB (publ) to Report Fiscal Year 2026 Final Results on Jul 03, 2026 Elekta AB (publ) announced that they will report fiscal year 2026 final results at 9:00 AM, Central European Standard Time on Jul 03, 2026 Annuncio • Feb 26
Elekta AB (publ), Annual General Meeting, Sep 03, 2026 Elekta AB (publ), Annual General Meeting, Sep 03, 2026. Annuncio • Jan 23
Elekta AB Appoints Tomas Eliasson as Vice Chair of the Board, Effective January 23, 2026 Elekta AB has established the role of Vice Chair of the Board and appointed Tomas Eliasson to this position, effective January 23, 2026. Tomas Eliasson has been a member of Elekta’s Board of Directors since 2023 and the Chair of its Audit Committee since 2024. He brings extensive experience from senior leadership and board roles in global industrial and technology-driven companies. His background includes deep expertise in finance, governance and strategy, supporting Elekta’s continued focus on long-term value creation. Annuncio • Jan 16
Elekta Receives FDA 510(K) Clearance for Elekta Evo Linear Accelerator Elekta announced that its Elekta Evo CT-Linac has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). This milestone makes the system available to radiation oncology professionals in the United States. When delivering radiation therapy, clinicians require high-quality images that allow them to identify tumors and organs-at-risk. Evo addresses this with Iris®? high-definition, AI-enhanced imaging, which allows physicians to see target areas and critical structures for every fraction with greater clarity. In Europe and other countries, Elekta Evo continues to gain traction, setting new benchmarks in radiation therapy as more clinics adopt its innovative treatment capabilities. Annuncio • Aug 28
Elekta AB (publ) Provides Earnings Guidance for the Second Quarter 2025-2026 and Reiterates Earnings Guidance for the Year 2025-2026 Elekta AB (publ) provided earnings guidance for the second quarter 2025-2026 and reiterated earnings guidance for the year 2025-2026. The company expects net sales for second quarter to be negatively impacted by a continued weak US development as well as a negative effect from last year's low order intake in China. However, The company expects sales in China to start to recover during the second half of 2025/26. Furthermore, company expect a continuous negative impact on earnings from FX at current exchange rates and from tariffs in second quarter.
The company reiterates full year 2025-2026 outlook, where the company expects net sales in constant currency to grow year-over-year. Annuncio • May 29
Elekta AB (publ), Annual General Meeting, Sep 04, 2025 Elekta AB (publ), Annual General Meeting, Sep 04, 2025. Annuncio • May 05
Elekta Announces Use of Its 1.5T Elekta Unity MR-Linac Elekta announced that use of its 1.5T Elekta Unity MR-Linac can enable doctors to reduce the radiation dose to key structures responsible for erection among men being treated for prostate cancer. The preliminary results of the ERECT (EREctile Function Preservation for Prostate Cancer Radiation Therapy) trial were presented by University Medical Center Utrecht (UMC Utrecht, the Netherlands) clinicians at the 2025 European Society for Radiotherapy and Oncology (ESTRO) annual congress, May 2-6 in Vienna, Austria. The ERECT Trial is a sub-study of MOMENTUM, the MR-Linac Consortium's platform registry. It showed reduced incidence of erectile dysfunction (ED) and preserved erectile function up to 18 months using MR-guided radiotherapy (MRgRT) compared to conventional radiotherapy in patients with localized prostate cancer. In the study, researchers used Elekta Unity MR- Linac to treat 70 intermediate risk prostate cancer patients with a radiation dose of 36.25 Gy over five fractions. According to UMC Utrecht radiation oncologist and trial principal investor, Jochem van der Voort van Zyp, MD, PhD, Unity's pristine MR image quality not only enabled detailed visualization of the prostate, but also that of critical structures needed to achieve and maintain an erection. This anatomy includes the neurovascular bundle, internal pudendal arteries, corpora cavernosa and penile bulb. The endpoint of this preliminary analysis was the incidence of ED - as reported by patients - at six, 12- and 18-months post-treatment, compared to a control group that received the same dosage without neurovascular sparing. ED incidence was significantly lower in ERECT patients at all time points (six months: 6% vs. 21%, 12 months: 8.5% vs. 38%, 18 months: 16% vs. 36%). MRI is the gold standard for visualizing the prostate and surrounding structures in diagnostic radiology. Elekta Unity MR-Liac is the world's first and only device to combine a high-field MRI with a linear accelerator and enables clinicians to use MRI to guide radiation delivery to tumor targets and avoid surrounding structures. In addition, while treatment is ongoing, the system allows clinicians to non-invasively monitor the position of the target. If for example, if a prostate shifts due to motion of the bowels or bladder filling, the radiation treatment can be discontinued to avoid unnecessary radiation to surrounding normal tissues. Declared Dividend • Dec 30
First half dividend of kr1.20 announced Shareholders will receive a dividend of kr1.20. Ex-date: 6th March 2025 Payment date: 12th March 2025 Dividend yield will be 25%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is not adequately covered by earnings (92% earnings payout ratio) nor is it covered by cash flows (157% cash payout ratio). The dividend has increased by an average of 1.8% per year over the past 10 years. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to grow by 1.7% to bring the payout ratio under control. EPS is expected to grow by 79% over the next 3 years, which is sufficient to bring the dividend into a sustainable range. Annuncio • Nov 01
Caroline Leksell Cooke Steps Down from Elekta AB's Board of Directors Elekta AB announced that Caroline Leksell Cooke will step down from her role on the Board of Directors, effective November 1, 2024. This follows the earlier announcement that Caroline Leksell Cooke will assume the role of Senior Vice President and Head of Neuro Solutions, effective the same date, and in connection therewith leave her position as a board member. Annuncio • Sep 27
Elekta AB Submits Elekta Evo to U.S. FDA for Premarket Approval Elekta AB announced that its AI-powered adaptive CT-Linear Accelerator, Elekta Evo has been submitted and is now pending 510(k) premarket approval from the U.S. Food and Drug Administration (FDA) - this, less than a week after Evo received CE mark for sales and marketing in the European Union. Declared Dividend • Sep 08
Dividend of kr1.20 announced Shareholders will receive a dividend of kr1.20. Ex-date: 6th March 2025 Payment date: 12th March 2025 Dividend yield will be 24%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is covered by earnings (81% earnings payout ratio) but not covered by cash flows (111% cash payout ratio). The dividend has increased by an average of 1.8% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 63% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Annuncio • Sep 06
Elekta AB (Publ) Approves Dividend, Payable on September 12, 2024, and on March 12, 2025, Respectively Elekta AB (publ) at its AGM held on September 5, 2024, approved dividend corresponding to SEK 2.40 per share and that the remaining profits are carried forward. The dividend is to be divided into two payments of SEK 1.20 per payment. The first record day is September 9, 2024. The second record day is March 7, 2025. The dividend is expected to be paid out on September 12, 2024, and on March 12, 2025, respectively. Upcoming Dividend • Aug 30
Upcoming dividend of kr1.20 per share Eligible shareholders must have bought the stock before 06 September 2024. Payment date: 12 September 2024. Payout ratio is on the higher end at 81%, and the cash payout ratio is above 100%. Trailing yield: 3.5%. Lower than top quartile of German dividend payers (4.8%). Higher than average of industry peers (1.8%). Reported Earnings • Aug 29
First quarter 2025 earnings released: EPS: kr0.18 (vs kr0.62 in 1Q 2024) First quarter 2025 results: EPS: kr0.18 (down from kr0.62 in 1Q 2024). Revenue: kr3.83b (flat on 1Q 2024). Net income: kr70.0m (down 71% from 1Q 2024). Profit margin: 1.8% (down from 6.2% in 1Q 2024). Revenue is forecast to grow 6.3% p.a. on average during the next 3 years, compared to a 6.4% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings. New Risk • Aug 28
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Dividend is not well covered by cash flows (112% cash payout ratio). Share price has been volatile over the past 3 months (7.0% average weekly change). Declared Dividend • Aug 04
Dividend of kr1.20 announced Shareholders will receive a dividend of kr1.20. Ex-date: 6th September 2024 Payment date: 12th September 2024 Dividend yield will be 26%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is covered by earnings (70% earnings payout ratio) but not covered by cash flows (112% cash payout ratio). The dividend has increased by an average of 4.8% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 50% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Reported Earnings • Jul 07
Full year 2024 earnings released: EPS: kr3.41 (vs kr2.47 in FY 2023) Full year 2024 results: EPS: kr3.41 (up from kr2.47 in FY 2023). Revenue: kr18.1b (up 7.4% from FY 2023). Net income: kr1.30b (up 38% from FY 2023). Profit margin: 7.2% (up from 5.6% in FY 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.1% p.a. on average during the next 3 years, compared to a 6.6% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings. Annuncio • Jul 06
Elekta AB (publ) to Report Q4, 2025 Results on May 28, 2025 Elekta AB (publ) announced that they will report Q4, 2025 results on May 28, 2025 Recent Insider Transactions • Jun 11
President & CEO recently bought €42k worth of stock On the 7th of June, Gustaf Salford bought around 7k shares on-market at roughly €5.98 per share. This transaction amounted to 12% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Gustaf has been a buyer over the last 12 months, purchasing a net total of €84k worth in shares. Annuncio • Jun 06
Elekta AB (publ) to Report Q3, 2025 Results on Feb 21, 2025 Elekta AB (publ) announced that they will report Q3, 2025 results on Feb 21, 2025 Reported Earnings • Jun 06
Full year 2024 earnings released: EPS: kr3.41 (vs kr2.47 in FY 2023) Full year 2024 results: EPS: kr3.41 (up from kr2.47 in FY 2023). Revenue: kr18.1b (up 7.4% from FY 2023). Net income: kr1.30b (up 38% from FY 2023). Profit margin: 7.2% (up from 5.6% in FY 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.6% p.a. on average during the next 3 years, compared to a 6.8% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 20% per year, which means it is significantly lagging earnings. Annuncio • Mar 02
Elekta AB (publ) Announces Resignation of Kelly Londy, Member of the Board Elekta AB announced that Kelly Londy, Member of the Board, will step down from her position and all board responsibilities, effective March 1, 2024. Ms. Londy has assumed a new senior executive role at another company, which will require her full attention. She has contributed significantly to Elekta’s Board and been greatly appreciated by her fellow board members. Elekta expresses its sincere gratitude to Ms. Londy for her dedicated service and wishes her continued success in her future role. Reported Earnings • Mar 01
Third quarter 2024 earnings released: EPS: kr0.80 (vs kr0.56 in 3Q 2023) Third quarter 2024 results: EPS: kr0.80 (up from kr0.56 in 3Q 2023). Revenue: kr4.54b (up 4.6% from 3Q 2023). Net income: kr305.0m (up 41% from 3Q 2023). Profit margin: 6.7% (up from 5.0% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.2% p.a. on average during the next 3 years, compared to a 6.7% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 15% per year, which means it is performing significantly worse than earnings. Annuncio • Feb 29
Elekta AB (publ) to Report Q2, 2025 Results on Nov 27, 2024 Elekta AB (publ) announced that they will report Q2, 2025 results on Nov 27, 2024 Upcoming Dividend • Feb 19
Upcoming dividend of kr1.20 per share Eligible shareholders must have bought the stock before 26 February 2024. Payment date: 01 March 2024. Payout ratio is a comfortable 68% but the company is paying out more than the cash it is generating. Trailing yield: 3.1%. Lower than top quartile of German dividend payers (5.1%). Higher than average of industry peers (1.6%). Reported Earnings • Dec 01
Second quarter 2024 earnings released: EPS: kr0.90 (vs kr0.32 in 2Q 2023) Second quarter 2024 results: EPS: kr0.90 (up from kr0.32 in 2Q 2023). Revenue: kr4.73b (up 16% from 2Q 2023). Net income: kr344.0m (up 182% from 2Q 2023). Profit margin: 7.3% (up from 3.0% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.3% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has fallen by 13% per year, which means it is performing significantly worse than earnings. Annuncio • Nov 01
Elekta AB (publ) Announces Composition of Nomination Committee Elekta AB (publ) announced that Annual General Meeting on August 24, 2023, the Chairman of the Board has convened the Nomination Committee for the 2024 Annual General Meeting by contacting the company's shareholders in terms of votes, in addition to the shareholder or shareholders represented by the Chairman himself. The procedure is described in detail in the notice to the 2020 Annual General Meeting. The Nomination Committee consists of: Laurent Leksell, in his capacity as Chairman of the Board of Elekta and representing his own and related parties' holdings; Thomas Wuolikainen, appointed by the Fourth Swedish National Pension Fund; Katarina Hammar, appointed by Nordea Funds; Patrik Jönsson, appointed by SEB Funds; Jesper Bergström, appointed by Handelsbanken Funds. Annuncio • Oct 24
Elekta AB (publ) (OM:EKTA B) agreed to acquire Xoft, Inc. from iCAD, Inc. (NasdaqCM:ICAD). Elekta AB (publ) (OM:EKTA B) agreed to acquire Xoft, Inc. from iCAD, Inc. (NasdaqCM:ICAD) on October 23, 2023. The intention is to complete the transaction during the second quarter of Elekta’s fiscal year 2023/24. Annuncio • Oct 13
Elekta AB (publ), Annual General Meeting, Sep 05, 2024 Elekta AB (publ), Annual General Meeting, Sep 05, 2024. Recent Insider Transactions • Sep 23
Founder & Chairman recently sold €5.1m worth of stock On the 20th of September, Laurent Leksell sold around 800k shares on-market at roughly €6.33 per share. This transaction amounted to 9.2% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Laurent's only on-market trade for the last 12 months. Reported Earnings • Aug 25
First quarter 2024 earnings released: EPS: kr0.62 (vs kr0.16 in 1Q 2023) First quarter 2024 results: EPS: kr0.62 (up from kr0.16 in 1Q 2023). Revenue: kr3.83b (up 15% from 1Q 2023). Net income: kr238.0m (up 297% from 1Q 2023). Profit margin: 6.2% (up from 1.8% in 1Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.0% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 11% per year whereas the company’s share price has fallen by 15% per year. Upcoming Dividend • Aug 18
Upcoming dividend of kr1.20 per share at 3.1% yield Eligible shareholders must have bought the stock before 25 August 2023. Payment date: 31 August 2023. Payout ratio is on the higher end at 97%, and the cash payout ratio is above 100%. Trailing yield: 3.1%. Lower than top quartile of German dividend payers (4.8%). Higher than average of industry peers (2.0%). Reported Earnings • Jul 09
Full year 2023 earnings released: EPS: kr2.47 (vs kr3.02 in FY 2022) Full year 2023 results: EPS: kr2.47 (down from kr3.02 in FY 2022). Revenue: kr16.9b (up 16% from FY 2022). Net income: kr943.0m (down 18% from FY 2022). Profit margin: 5.6% (down from 7.9% in FY 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 6.5% p.a. on average during the next 3 years, compared to a 6.1% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 11% per year whereas the company’s share price has fallen by 6% per year. Annuncio • Jun 30
Johan Malmquist Declines Re-Election as Director of Elekta AB (Publ) Elekta AB (publ) announced that 2023 Annual General Meeting to held on 24 August 2023, Johan Malmquist has declined re-election as director of the company. Buying Opportunity • May 31
Now 20% undervalued after recent price drop Over the last 90 days, the stock is down 1.8%. The fair value is estimated to be €8.89, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.5% over the last 3 years. Earnings per share has declined by 11%. For the next 3 years, revenue is forecast to grow by 5.5% per annum. Earnings is also forecast to grow by 23% per annum over the same time period. Reported Earnings • May 26
Full year 2023 earnings released: EPS: kr2.47 (vs kr3.02 in FY 2022) Full year 2023 results: EPS: kr2.47 (down from kr3.02 in FY 2022). Revenue: kr16.9b (up 16% from FY 2022). Net income: kr943.0m (down 18% from FY 2022). Profit margin: 5.6% (down from 7.9% in FY 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 5.1% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 11% per year whereas the company’s share price has fallen by 9% per year. Annuncio • May 13
Elekta AB (Publ) Announces the Launch of the First Phase of Elekta ONE Elekta AB (publ) is excited to announced the launch of the first phase of Elekta ONE, its most comprehensive and advanced software portfolio for oncology departments and clinics, including radiation therapy planning, comprehensive treatment management, and delivery. It brings all Elekta software products, solutions and services under one umbrella providing all users with one unified software experience. Previously, many cancer clinics have wrestled with stand-alone, closed systems, each with a different purpose. The result has been an unfavorable user experience and steep learning curve, adding pressure to an already strained resource: the clinical team. Elekta ONE aims to improve efficiency in the clinic by as much as 50%, eventually through smarter workflows, increased automation, and by learning from every patient treated. Its workflow-driven approach and deep integration between applications allows information to flow freely, giving clinicians a seamless user experience. Buying Opportunity • May 09
Now 21% undervalued Over the last 90 days, the stock is up 13%. The fair value is estimated to be €9.68, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has declined by 9.7%. For the next 3 years, revenue is forecast to grow by 7.4% per annum. Earnings is also forecast to grow by 23% per annum over the same time period. Reported Earnings • Feb 26
Third quarter 2023 earnings released Third quarter 2023 results: Revenue: kr4.34b (up 20% from 3Q 2022). Net income: kr216.0m (down 5.7% from 3Q 2022). Profit margin: 5.0% (down from 6.4% in 3Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 6.4% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 7% per year whereas the company’s share price has fallen by 8% per year. Valuation Update With 7 Day Price Move • Feb 25
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to €7.73, the stock trades at a forward P/E ratio of 28x. Average forward P/E is 27x in the Medical Equipment industry in Europe. Total loss to shareholders of 14% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €12.31 per share. Upcoming Dividend • Feb 17
Upcoming dividend of kr1.20 per share at 3.1% yield Eligible shareholders must have bought the stock before 24 February 2023. Payment date: 02 March 2023. The company is paying out more than 100% of its profits and is cash flow negative. Trailing yield: 3.1%. Lower than top quartile of German dividend payers (4.6%). Higher than average of industry peers (1.7%). Annuncio • Feb 14
Elekta AB (publ) (OM:EKTA B) entered into an agreement to acquire business assets of Premier Business Inter. Elekta AB (publ) (OM:EKTA B) entered into an agreement to acquire business assets of Premier Business Inter on February 13, 2023. The first quarter of Elekta’s fiscal year 2023-2024. Annuncio • Dec 13
First Ever Patient Treated for Pancreatic Cancer with New Advanced Radiotherapy Motion Management Using Elekta Unity MR-Linac Elekta AB (publ) announced that UTRECHT - A milestone was reached in radiation therapy last week as the first patients completed their full course of radiation therapy treatment with Elekta (EKTA-B.ST) Unity MR-Linac using Comprehensive Motion Management (CMM) with True Tracking and automatic gating functionalities. A patient with pancreatic cancer was treated at University Medical Center (UMC) Utrecht using Unity's CMM developments, which can continuously calculate the movement of the tumor and correct for it automatically. This first ever treatment delivery using CMM went smoothly and did not increase the total treatment time per fraction. The beam wasautomatically turned on when the patient was in the exhale phase of breathing, so they were not required to hold their breath for extended periods, according to Dr. Martijn Intven, a radiation oncologist at UMC Utrecht. With automatic gating, supported by Elekta's unique True Tracking algorithms, the radiation beam is automatically turned off when the tumor moves outside of the beam, ensuring treatment is always focused on the target. For the first time ever in radiotherapy, Elekta Unity's True Tracking provides continuous tracking of the 3D position of a target anywhere in the body, non-invasively and without surrogates. In addition, CMM offers rapid compensation for sustained intrafraction drift: realigning the beam with the new position of the target without the need to re-acquire a 3D image. UMC Utrecht was Elekta's initial research partner in the development of Elekta Unity, aproject that has extended over two decades. During this time, clinicians at UMC have helped pioneer radiation treatment that responds to movement of tumors during delivery. Reported Earnings • Nov 25
Second quarter 2023 earnings released Second quarter 2023 results: Revenue: kr4.08b (up 10% from 2Q 2022). Net income: kr122.0m (down 68% from 2Q 2022). Profit margin: 3.0% (down from 10% in 2Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 6.8% p.a. on average during the next 3 years, compared to a 5.7% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has fallen by 22% per year, which means it is performing significantly worse than earnings. Annuncio • Nov 24
Elekta AB (publ), Annual General Meeting, Aug 24, 2023 Elekta AB (publ), Annual General Meeting, Aug 24, 2023. Annuncio • Nov 18
Swedish and Jordanian Royalty Inaugurate Elekta AB (publ) Radiation Therapy Devices for Cancer and Brain Disease Dignitaries from Sweden and Jordan attended the inauguration of two of Elekta's cancer care technologies, including an advanced linear accelerator used to deliver radiation to treat people with cancer and a Leksell Gamma Knife radiosurgery system, which is used to treat a range of neurosurgical and oncological brain indications. The ceremony was held on November 16 at King Hussein Cancer Center together with King Hussein Cancer Foundation in Amman. Representing Elekta, Caroline Leksell Cooke, Member of Elekta's Board of Directors and granddaughter of Professor Lars Leksell, inventor of the Gamma Knife, spoke of her pride in the company's collaboration with health care facilities in Jordan and support to improve the lives of some of the 11,500 people diagnosed with cancer each year. The first Elekta linac and Gamma Knife were installed in Jordan in 2005, with successive upgrades and new technology since. Today, a wide spectrum of cancer is managed with the country's 15 Elekta linacs, two Gamma Knife systems, and brachytherapy solutions. Their Majesties the King and Queen of Sweden, Her Royal Highness Princess Ghida Talal, who is Chairperson of KHCC, His Royal Highness Prince Talal bin Muhammad, Caroline Leksell Cooke, the Swedish Ambassador to Jordan H.E. Alexandra Rydmark, and Dr. Asem Mansour KHCC General Director, were among those attending the event. The inauguration ceremony was part of a three-day state visit by Sweden's King Carl XVI Gustaf and Queen Silvia, together with Sweden's Minister of Foreign Affairs, H.E.Tobias Billström. During their visit, they will also pay tribute to the 40th anniversary of Sweden's diplomatic presence in Jordan. Board Change • Nov 16
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 4 highly experienced directors. Independent Director Kelly Londy was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Annuncio • Oct 28
Elekta AB (publ) Announces Elekta Esprit Receives FDA 510(k) Clearance Elekta AB (publ) announced that Elekta Esprit, a new Leksell Gamma Knife® radiosurgery platform, received FDA 510(k) clearance. This milestone makes the system available to clinicians and people with brain disease in the U.S., as well as opening the door to other countries where FDA approval is recognized. Leksell Gamma Knife has been designed as a gentler alternative to open surgery and conventional radiotherapy. It can target the smallest and most challenging intracranial tumors and lesions with minimal effect on healthy tissue. This vital precision safeguards motor, sensory and neurocognitive function to help protect the mind and the person. With a variety of innovations now available in a single platform, Esprit continues to offer clinicians the option of frameless or frame-based workflows with a frame that provides superior visualization. Remote accessibility and collaboration tools for the treatment team are designed to meet the needs of changing environments. Esprit provides the accuracy to treat even the most challenging targets while delivering a gentler more personalized approach to radiosurgery. Leksell Gamma Knife has over 50 years of clinical evidence and remains the gold standard of intracranial radiosurgery. The U.S. has the largest installed base of Gamma Knife systems, whose users have contributed to driving the standard of care forward. Continuous advances in its design have resulted in extremely fast automated treatment planning for clinicians, and Esprit is ideal for safely treating a broad range of indications, including multiple metastases, arteriovenous malformations, trigeminal neuralgia and vestibular schwannoma. Annuncio • Oct 26
Elekta Unity Demonstrates Promising Quality of Life Outcomes for Pancreas and Prostate Cancers At Astro Annual Meeting Elekta announced two new reports from the MOMENTUM Study highlighting the clinical impact of Elekta Unity MR-Linac in treating pancreas and prostate cancers. The abstracts were presented at the American Society for Radiation Oncology (ASTRO) Annual Meeting, in San Antonio, Texas. These reports add to a growing body of evidence showing that enhanced precision radiotherapy using MR-guided on-line adaptation may improve outcomes in both pancreas and prostate cancers, two common treatment indications for radiotherapy. Elekta Unity is the world’s first and only MR-Linac to unite diagnostic quality high field (1.5T) MRI with a linear accelerator to deliver unprecedented visibility and precision, thus enabling personalized radiotherapy. The MOMENTUM Study is the largest prospective international registry of high field MR-guided therapy, currently enrolling patients from 15 major cancer centers in North America, Europe and Australia. In the study of pancreas tumors, which are historically treatment resistant, 80 patients treated with an ablative radiation dose using MR-guided online adaption were enrolled and surveyed using standardized quality-of-life questionnaires. Patients reported limited adverse effects and stable global health status out to three months. Importantly, 67% of patients were alive one year after the end of treatment. In the study of prostate cancers, 218 patients were enrolled and followed with standardized quality-of-life questionnaires. Approximately half of the patients were treated using both MR-guidance and on-line adaptation functionality on Elekta Unity while the remaining half were treated using only MR-guidance without on-line adaptation. As expected, investigators observed a decline in quality-of-life scores three months after the end of treatment in the cohort treated with MR-guidance alone. However, no significant decline in quality of life was observed in the cohort of prostate cancers treated using both MR-guidance and on-line adaptation. Annuncio • Sep 19
Elekta AB (publ)(OM:EKTA B) dropped from FTSE All-World Index (USD) Elekta AB (publ)(OM:EKTA B) dropped from FTSE All-World Index (USD) Reported Earnings • Aug 26
First quarter 2023 earnings released: EPS: kr0.16 (vs kr0.33 in 1Q 2022) First quarter 2023 results: EPS: kr0.16 (down from kr0.33 in 1Q 2022). Revenue: kr3.33b (up 11% from 1Q 2022). Net income: kr60.0m (down 53% from 1Q 2022). Profit margin: 1.8% (down from 4.2% in 1Q 2022). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 8.5%, compared to a 7.8% growth forecast for the Medical Equipment industry in Germany. Upcoming Dividend • Aug 19
Upcoming dividend of kr1.20 per share Eligible shareholders must have bought the stock before 26 August 2022. Payment date: 01 September 2022. Payout ratio is on the higher end at 79%, and the cash payout ratio is above 100%. Trailing yield: 3.3%. Lower than top quartile of German dividend payers (4.5%). Higher than average of industry peers (1.2%). Reported Earnings • Jul 13
Full year 2022 earnings released: EPS: kr3.02 (vs kr3.28 in FY 2021) Full year 2022 results: EPS: kr3.02 (down from kr3.28 in FY 2021). Revenue: kr14.5b (up 5.7% from FY 2021). Net income: kr1.15b (down 8.0% from FY 2021). Profit margin: 7.9% (down from 9.1% in FY 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 9.4%, compared to a 8.4% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings. Reported Earnings • May 26
Full year 2022 earnings released: EPS: kr3.02 (vs kr3.28 in FY 2021) Full year 2022 results: EPS: kr3.02 (down from kr3.28 in FY 2021). Revenue: kr14.5b (up 5.7% from FY 2021). Net income: kr1.15b (down 8.0% from FY 2021). Profit margin: 7.9% (down from 9.1% in FY 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 8.4%, compared to a 7.3% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings. Annuncio • May 26
Elekta AB (Publ) Proposes Dividend for the Fiscal Year 2021/22 The Board of Directors of Elekta AB (publ) proposed a dividend of SEK 2.40 (SEK 2.20) per share (paid in two installments) for the fiscal year 2021/22. Annuncio • May 08
Elekta Launches New Radiosurgery System: Elekta Esprit Elekta AB (publ) has evolved radiosurgery to an unprecedented level with the launch of Elekta Esprit. This latest and most advanced system will offer significantly faster automated treatment planning for clinicians, more personalized and patient-friendly treatments, and a degree of precision able to protect the mind and the person. With a variety of innovations now available in a single platform, Esprit offers clinicians superior visualization, as well as remote accessibility and collaboration tools for the treatment team. And it provides the accuracy to treat even the most challenging targets while delivering a gentler more personalized approach to radiosurgery. Board Change • Apr 27
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 4 highly experienced directors. Independent Director Cecilia Wikström was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Recent Insider Transactions • Mar 10
President of Brachy Solutions recently bought €30k worth of stock On the 2nd of March, John Lapré bought around 4k shares on-market at roughly €7.41 per share. In the last 3 months, there was an even bigger purchase from another insider worth €145k. Insiders have collectively bought €2.1m more in shares than they have sold in the last 12 months. Recent Insider Transactions • Mar 04
Insider recently bought €49k worth of stock On the 24th of February, Verena Schiller bought around 6k shares on-market at roughly €7.58 per share. In the last 3 months, there was an even bigger purchase from another insider worth €145k. Insiders have collectively bought €2.1m more in shares than they have sold in the last 12 months. Reported Earnings • Feb 25
Third quarter 2022 earnings: Revenues in line with analyst expectations Third quarter 2022 results: Revenue: kr3.60b (flat on 3Q 2021). Net income: kr229.0m (down 29% from 3Q 2021). Profit margin: 6.4% (down from 9.0% in 3Q 2021). Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 11%, compared to a 11% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings. Annuncio • Feb 24
Elekta AB (publ), Annual General Meeting, Aug 25, 2022 Elekta AB (publ), Annual General Meeting, Aug 25, 2022. Valuation Update With 7 Day Price Move • Feb 19
Investor sentiment deteriorated over the past week After last week's 16% share price decline to €7.79, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 29x in the Medical Equipment industry in Germany. Total loss to shareholders of 32% over the past three years. Upcoming Dividend • Feb 18
Upcoming dividend of kr1.10 per share Eligible shareholders must have bought the stock before 25 February 2022. Payment date: 03 March 2022. Payout ratio is a comfortable 72% and the cash payout ratio is 80%. Trailing yield: 2.6%. Lower than top quartile of German dividend payers (3.3%). Higher than average of industry peers (1.1%). Recent Insider Transactions • Dec 18
President & CEO recently bought €145k worth of stock On the 16th of December, Gustaf Salford bought around 14k shares on-market at roughly €10.38 per share. In the last 3 months, there was an even bigger purchase from another insider worth €4.8m. Gustaf has been a buyer over the last 12 months, purchasing a net total of €301k worth in shares. 
